Heat Shock Protein 90 Family Isoforms as Prognostic Biomarkers and Their Correlations with Immune Infiltration in Breast Cancer
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Background. The heat shock protein 90 (HSP90s) family is composed of molecular chaperones composed of four isoforms in humans, which has been widely reported as unregulated in various kinds of cancers. Nevertheless, the role of each HSP90s isoform in prognosis and immune infiltration in distinct subtypes of breast cancer (BRAC) remains unclear. Methods. Public online databases including the Oncomine, UALCAN, Kaplan‐Meier Plotter, Tumor IMmune Estimation Resource (TIMER), Gene Expression Profiling Interactive Analysis (GEPIA), GeneMANIA, and Database for Annotation, Visualization, and Integrated Discovery (DAVID) were integrated to perform bioinformatic analyses and to explore the possible associations among HSP90s gene expression, prognosis, and immune infiltration in BRAC. Results. The mRNA expression of all HSP90s members was elevated in distinct clinical stages and subtypes of BRAC, compared with the normal breast tissue (P < 0.05). Overexpressed HSP90AA1 was associated with poor prognosis, particularly, both short overall survival (OS) and release‐free survival (RFS) in Basal‐like BRAC patients; overexpressed HSP90AB1 and HSP90B1 were both associated with poor RFS in Luminal A BRAC patients, while overexpressed TRAP1 was associated with favorable RFS in Luminal A BRAC patients. Moreover, HSP90s gene expression in BRAC showed correlations with the infiltration of CD8+ T cells, neutrophils, macrophages, and dendritic cells (DCs), as well as the activation of tumor‐associated macrophages (TAMs), DCs, and CD4+ helper T (Th) cells. The underlying mechanisms of HSP90s modulating tumor‐infiltrating immune cells (TIICs) might be related with their functions in antigen processing and presentation, major histocompatibility complex (MHC) binding, and assisting client proteins. Conclusion. This study demonstrated that HSP90s family genes were overexpressed and might be serve as prognostic biomarkers in subtypes of BRAC. It might be a novel breakthrough point of BRAC treatment to regulate immune infiltration in BRAC microenvironment for more effective anticancer immunity through pharmacological intervention of HSP90s.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple investigations have revealed that HSP90AB1 facilitates tumorigenesis in a spectrum of cancers, including gastric cancer, breast cancer, non-small cell lung cancer (NSCLC), hepatocellular carcinoma, and head and neck squamous cell carcinoma [13–18].”
From Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer (2024) · cites this paper as [14]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · cited 1×
“Despite that mortality has declined by improvements in screening and adjuvant systemic treatments, breast cancer (BRAC) is still the most common cancer and the leading cause of cancer-related death for females worldwide [1, 2].”
BackgroundPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Cancer statistics in China, 2015
Chen, W., Zheng, R., Baade, P. D., Zhang, S., Zeng, H., Bray, F., Jemal, A., Yu, X. Q., & He, J. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21338 · Cited by 17,038 · cited 1×
“Despite that mortality has declined by improvements in screening and adjuvant systemic treatments, breast cancer (BRAC) is still the most common cancer and the leading cause of cancer-related death for females worldwide [1, 2].”
BackgroundGEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
Tang, Z., Li, C., Kang, B., Gao, G., Li, C., & Zhang, Z. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx247 · Cited by 9,849 · cited 1×
“Gene Expression Profiling Interactive Analysis (GEPIA) is a database used to analyze RNA-seq data, based on 9,736 tumors and 8,587 normal samples from the TCGA and the GTEx projects [25].”
MethodUALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
Chandrashekar, D. S., Bashel, B., Balasubramanya, S. A. H., Creighton, C. J., Ponce-Rodriguez, I., Chakravarthi, B. V. S. K., & Varambally, S. (2017) · Neoplasia · doi:10.1016/j.neo.2017.05.002 · Cited by 6,086 · cited 1×
“The UALCAN database is an interactive web portal for in-depth gene expression analysis using RNA sequencing (RNA-seq) and clinical data from the Cancer Genome Atlas (TCGA) project [22].”
MethodTIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells
Li, T., Fan, J., Wang, B., Traugh, N., Chen, Q., Liu, J. S., Li, B., & Liu, X. S. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0307 · Cited by 5,913 · cited 4×
“The UALCAN database is an interactive web portal for in-depth gene expression analysis using RNA sequencing (RNA-seq) and clinical data from the Cancer Genome Atlas (TCGA) project [22].”
BackgroundInfluentialGyörffy, B., Lanczky, A., Eklund, A. C., Denkert, C., Budczies, J., Li, Q., & Szallasi, Z. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0674-9 · Cited by 4,169 · cited 1×
“The Kaplan-Meier (KM) Plotter is an online database that provides 54,000 gene expression profiles with patients’ survival information in twenty-one kinds of cancers, which harbors gene chip and RNA-seq data from GEO, TCGA, and European Genome-phenome Archive [23].”
BackgroundGoldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., Albain, K. S., André, F., Bergh, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt303 · Cited by 3,746
Differentiation of Effector CD4 T Cell Populations
Zhu, J., Yamane, H., & Paul, W. E. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101212 · Cited by 3,452 · cited 1×
“Naive CD4+ T cells can differentiate into several lineages of Th cells, including Th1, Th2, Th17, Treg, and Tfh, distinguished by their patterns of cytokine production and biological functions [48].”
BackgroundThe immune contexture in cancer prognosis and treatment
Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263 · cited 1×
“Since the density, subpopulations, and activity of TIICs could lead to distinct outcomes and therapeutic responses of different subtypes of BRAC [33, 34], relations between HSP90s gene expression and immune infiltration in different subtypes of BRCA were analyzed as well.”
BackgroundRhodes, D. R., Kalyana-Sundaram, S., Mahavisno, V., Varambally, R., Yu, J., Briggs, B. B., Barrette, T. R., Anstet, M. J., Kincead-Beal, C., Kulkarni, P., et al. (2007) · Neoplasia · doi:10.1593/neo.07112 · Cited by 2,060 · cited 2×
“The Oncomine is an online data mining server unifying a large compendium of microarray data across 18,000 cancer samples, combined the published literature, the Stanford Microarray Database and the NCBI Gene Expression Omnibus (GEO) [21].”
MethodFranz, M., Rodriguez, H., Lopes, C., Zuberi, K., Montojo, J., Bader, G. D., & Morris, Q. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky311 · Cited by 1,413 · cited 1×
“GeneMANIA is an online tool for investigation into associated or similar genes for target genes, through analysis of physical and functional associations, such as colocalization, coexpression, and physical interaction [28].”
MethodClinical implications of the intrinsic molecular subtypes of breast cancer
Prat, A., Pineda, E., Adamo, B., Galván, P., Fernández, A., Gaba, L., Díez, M., Viladot, M., Arance, A., & Muñoz, M. (2015) · The Breast · doi:10.1016/j.breast.2015.07.008 · Cited by 1,319 · cited 1×
“BRAC is a highly heterogenous disease in histology and molecular, determining different incidence, biology, treatment sensitiveness, and prognosis [3, 4].”
BackgroundAdams, S., Gray, R. J., Demaria, S., Goldstein, L., Perez, E. A., Shulman, L. N., Martino, S., Wang, M., Jones, V. E., Saphner, T. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.55.0491 · Cited by 1,299
Systematic pan-cancer analysis of tumour purity
Aran, D., Sirota, M., & Butte, A. J. (2015) · Nature Communications · doi:10.1038/ncomms9971 · Cited by 1,216 · cited 1×
“Because the evaluation of immune infiltration is influenced by tumor purity, which means the proportion of cancer cells in the admixture [32], the correlation analysis was adjusted for corresponding tumor purity.”
MethodCD4+ follicular helper T cell infiltration predicts breast cancer survival
Gu-Trantien, C., Loi, S., Garaud, S., Equeter, C., Libin, M., de Wind, A., Ravoet, M., Le Buanec, H., Sibille, C., Manfouo-Foutsop, G., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67428 · Cited by 1,070
Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?
Neckers, L., & Workman, P. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1000 · Cited by 891 · cited 1×
“Thus, cancer cells are usually addicted to HSP90s to relieve the intracellular stress caused by their malignant lifestyle, which consequently facilitates cancer progression and treatment resistance [35, 36].”
BackgroundClinical relevance of host immunity in breast cancer: from TILs to the clinic
Savas, P., Salgado, R., Denkert, C., Sotiriou, C., Darcy, P. K., Smyth, M. J., & Loi, S. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.215 · Cited by 890 · cited 1×
“Once stimulated by cancer antigens and cytokines secreted by Th1 cells, they further proliferate and differentiate into effective cytotoxic cells with specific cancer-killing capabilities [10, 40, 41].”
BackgroundX chromosomal abnormalities in basal-like human breast cancer
Richardson, A. L., Wang, Z. C., De Nicolo, A., Lu, X., Brown, M., Miron, A., Liao, X., Iglehart, J. D., Livingston, D. M., & Ganesan, S. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.01.013 · Cited by 869 · cited 1×
“84 [29] HSP90AB1 Mucinous breast carcinoma vs.”
Medrek, C., Pontén, F., Jirström, K., & Leandersson, K. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-306 · Cited by 647
Lehmann, B. D., & Pietenpol, J. A. (2014) · The Journal of Pathology · doi:10.1002/path.4280 · Cited by 495
Different Gene Expression Patterns in Invasive Lobular and Ductal Carcinomas of the Breast
Zhao, H., Langerød, A., Ji, Y., Nowels, K. W., Nesland, J. M., Tibshirani, R., Bukholm, I. K., Kåresen, R., Botstein, D., Børresen-Dale, A.-L., et al. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e03-11-0786 · Cited by 445 · cited 1×
“373 [31] 3 BioMed Research International”
Tumor-associated macrophages in breast cancer: Innocent bystander or important player?
Qiu, S.-Q., Waaijer, S. J. H., Zwager, M. C., de Vries, E. G. E., van der Vegt, B., & Schröder, C. P. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.08.010 · Cited by 425
TIM-3 regulates CD103+ dendritic cell function and response to chemotherapy in breast cancer
de Mingo Pulido, Á., Gardner, A., Hiebler, S., Soliman, H., Rugo, H. S., Krummel, M. F., Coussens, L. M., & Ruffell, B. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.11.019 · Cited by 388
Mechanisms of Hsp90 regulation
Prodromou, C. (2016) · Biochemical Journal · doi:10.1042/bcj20160005 · Cited by 311 · cited 1×
“The client proteins of HSP90s include receptor tyrosine kinases, transcription factors, steroid hormone receptors, and cell cycle regulatory proteins, all of which play essential roles in cell survival and proliferation, as well as oncogenesis and malignancy of tumor [13].”
BackgroundNatural and therapy-induced immunosurveillance in breast cancer
Kroemer, G., Senovilla, L., Galluzzi, L., André, F., & Zitvogel, L. (2015) · Nature Medicine · doi:10.1038/nm.3944 · Cited by 310 · cited 1×
“Since the density, subpopulations, and activity of TIICs could lead to distinct outcomes and therapeutic responses of different subtypes of BRAC [33, 34], relations between HSP90s gene expression and immune infiltration in different subtypes of BRCA were analyzed as well.”
BackgroundLAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers
Pan, J.-H., Zhou, H., Cooper, L., Huang, J.-L., Zhu, S.-B., Zhao, X.-X., Ding, H., Pan, Y.-L., & Rong, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00006 · Cited by 300
Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer
Tang, X. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.01.024 · Cited by 276
Liu, S., Foulkes, W. D., Leung, S., Gao, D., Lau, S., Kos, Z., & Nielsen, T. O. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0432-8 · Cited by 236 · cited 1×
“Treg cells, especially the FOXP3+ ones, suppress immune responses and maintain cancer immune tolerance, the frequency of which has been applied as an independent risk factor of cancer relapse [51, 52].”
BackgroundRelevance of tumor-infiltrating lymphocytes in breast cancer
Dushyanthen, S., Beavis, P. A., Savas, P., Teo, Z. L., Zhou, C., Mansour, M., Darcy, P. K., & Loi, S. (2015) · BMC Medicine · doi:10.1186/s12916-015-0431-3 · Cited by 227
Adjustment of dendritic cells to the breast-cancer microenvironment is subset specific
Michea, P., Noël, F., Zakine, E., Czerwinska, U., Sirven, P., Abouzid, O., Goudot, C., Scholer-Dahirel, A., Vincent-Salomon, A., Reyal, F., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0145-8 · Cited by 223 · cited 1×
“DCs are antigen-presenting cells (APCs) specialized in triggering de novo T cell responses, and they also maintain the response effectiveness within the peripheral tissues [46, 47].”
BackgroundBurugu, S., Asleh-Aburaya, K., & Nielsen, T. O. (2017) · Breast Cancer · doi:10.1007/s12282-016-0698-z · Cited by 222 · cited 1×
“The role of tumor-associated neutrophils in BRAC is still unclear, but some preclinical studies identified their immunosuppression by reducing T cell proliferation [42].”
BackgroundMaximizing the Therapeutic Potential of HSP90 Inhibitors
Butler, L. M., Ferraldeschi, R., Armstrong, H. K., Centenera, M. M., & Workman, P. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0234 · Cited by 208 · cited 2×
“In this context, HSP90s are frequently observed overregulated in a wide range of cancers, and numerous HSP90s inhibitors are under trial as promising agents for cancer [11].”
BackgroundCheng, Q., Chang, J. T., Geradts, J., Neckers, L. M., Haystead, T., Spector, N. L., & Lyerly, H. K. (2012) · Breast Cancer Research · doi:10.1186/bcr3168 · Cited by 182 · cited 1×
“+/HER2− patients, respectively, which was quite inconsistent with our findings [16].”
ResultHSP90AB1: Helping the good and the bad
Haase, M., & Fitze, G. (2016) · Gene · doi:10.1016/j.gene.2015.08.063 · Cited by 179 · cited 2×
“These proteins are encoded by four real genes in humans, HSP90AA1, HSP90AB1, HSP90B1, and TRAP1 [17].”
BackgroundImmune Landscape of Breast Cancers
Nagarajan, D., & McArdle, S. (2018) · Biomedicines · doi:10.3390/biomedicines6010020 · Cited by 152 · cited 2×
“BRAC is a highly heterogenous disease in histology and molecular, determining different incidence, biology, treatment sensitiveness, and prognosis [3, 4].”
BackgroundShou, J., Zhang, Z., Lai, Y., Chen, Z., & Huang, J. (2016) · BMC Cancer · doi:10.1186/s12885-016-2732-0 · Cited by 144 · cited 1×
“CD4+ regulatory T (Treg) cells and M2 macrophages suppress effective anticancer immunity [6, 7].”
BackgroundTumor-infiltrating lymphocytes in breast cancer according to tumor subtype: Current state of the art
Solinas, C., Carbognin, L., Silva, P. D., Criscitiello, C., & Lambertini, M. (2017) · The Breast · doi:10.1016/j.breast.2017.07.005 · Cited by 119 · cited 1×
“Once stimulated by cancer antigens and cytokines secreted by Th1 cells, they further proliferate and differentiate into effective cytotoxic cells with specific cancer-killing capabilities [10, 40, 41].”
BackgroundClients and Oncogenic Roles of Molecular Chaperone gp96/grp94
A. Ansa-Addo, E., Thaxton, J., Hong, F., X. Wu, B., Zhang, Y., W. Fugle, C., Metelli, A., Riesenberg, B., Williams, K., T. Gewirth, D., et al. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160413141613 · Cited by 102
TRAP1 Regulation of Cancer Metabolism: Dual Role as Oncogene or Tumor Suppressor
Matassa, D. S., Agliarulo, I., Avolio, R., Landriscina, M., & Esposito, F. (2018) · Genes · doi:10.3390/genes9040195 · Cited by 98 · cited 1×
“And TRAP1 was described to be involved in energetic metabolism in various cancer cells and was often associated with treatment resistance, but the exact role of which remains controversial [14].”
BackgroundHeat shock proteins create a signature to predict the clinical outcome in breast cancer
Klimczak, M., Biecek, P., Żylicz, M., & Żylicz, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-43556-1 · Cited by 97 · cited 1×
“A research illuminated that HSP90AA1 was overexpressed in BRAC and was correlated with shorter OS and aggressive clinicopathological features, including high clinical stage, large tumors, and lymph node involvement [37].”
Li, L., Feng, Q., & Wang, X. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.03.007 · Cited by 93 · cited 1×
“035 [30] HSP90B1 Lobular breast carcinoma vs.”
Cawthorn, T. R., Moreno, J. C. A., Dharsee, M., Tran‐Thanh, D., Ackloo, S. Z., Zhu, P. H., Sardana, G., Chen, J., Kupchak, P., Jacks, L. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030992 · Cited by 91 · cited 1×
“Elevated protein expression of HSP90B1 was reported to be closely linked to the progression, distant metastasis, and decreased OS in BRAC patients [38, 39].”
BackgroundHSP90 and Immune Modulation in Cancer
Graner, M. W. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.10.001 · Cited by 90 · cited 2×
“What is more, HSP90s are reported to modulate immune processes, such as antigen presentation and activation of lymphocyte [19, 20].”
BackgroundA Role for T-Lymphocytes in Human Breast Cancer and in Canine Mammary Tumors
Carvalho, M. I., Pires, I. C. R., Prada, J., & QUEIROGA, F. L. (2014) · BioMed Research International · doi:10.1155/2014/130894 · Cited by 81 · cited 1×
“Thus, a higher value of Th1/Th2 is an indicator of better outcomes in cancer patients [49].”
BackgroundLiu, W., Li, J., Zhang, P., Hou, Q., Feng, S., Liu, L., Cui, D., Shi, H., Fu, Y., & Luo, Y. (2019) · Cancer Science · doi:10.1111/cas.14143 · Cited by 78
Proia, D. A., & Kaufmann, G. F. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0057 · Cited by 77 · cited 2×
“What is more, HSP90s are reported to modulate immune processes, such as antigen presentation and activation of lymphocyte [19, 20].”
BackgroundThe role of IL17B-IL17RB signaling pathway in breast cancer
Alinejad, V., Dolati, S., Motallebnezhad, M., & Yousefi, M. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.01.120 · Cited by 77 · cited 1×
“Th17 cells have exceptional roles in the development and progression of BRAC, which sustain procancer chronic inflammation through production of proinflammatory cytokines [50].”
BackgroundMolecular Pathways: Targeting Hsp90—Who Benefits and Who Does Not
Scaltriti, M., Dawood, S. S., & Cortés, J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2138 · Cited by 72 · cited 1×
“The heat shock protein 90 (HSP90s) family is composed of ubiquitously ATP-dependent molecular chaperones assisting in folding newly synthesized proteins or stabilizing denatured proteins under stress [11, 12].”
BackgroundRegulatory T cells in breast cancer as a potent anti-cancer therapeutic target
Hashemi, V., Maleki, L. A., Esmaily, M., Masjedi, A., Ghalamfarsa, G., Namdar, A., Yousefi, M., Yousefi, B., & Jadidi‐Niaragh, F. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.106087 · Cited by 61 · cited 1×
“Treg cells, especially the FOXP3+ ones, suppress immune responses and maintain cancer immune tolerance, the frequency of which has been applied as an independent risk factor of cancer relapse [51, 52].”
BackgroundMicrobial and human heat shock proteins as ‘danger signals’ in sarcoidosis
Dubaniewicz, A. (2013) · Human Immunology · doi:10.1016/j.humimm.2013.08.275 · Cited by 55 · cited 1×
“HSP90s exposed on the surfaces of dying cancer cells are kinds of “danger signals” to prompt APC activation and consequently stimulate effector T cells [54].”
BackgroundThe role of immune infiltrates as prognostic biomarkers in patients with breast cancer
Baxevanis, C. N., Sofopoulos, M., Fortis, S. P., & Perez, S. A. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02327-7 · Cited by 54 · cited 2×
“Although the development of immunotherapy has revolutionized the area of cancer, the clinical efficacy is still limited [6].”
BackgroundHarano, K., Wang, Y., Lim, B., Seitz, R. S., Morris, S. W., Bailey, D. B., Hout, D. R., Skelton, R. L., Ring, B. Z., Masuda, H., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0204513 · Cited by 51
Haggerty, T. J., Dunn, I. S., Rose, L. B., Newton, E. E., Pandolfi, F., & Kurnick, J. T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114506 · Cited by 30 · cited 1×
“On the one hand, HSP90s inhibition could increase the expression of tumor-specific antigens and MHC I-complexed antigens, which synergistically potentiate immunogenicity, thus enhancing tumor surveillance [55, 56].”
BackgroundImmune microenvironment as a factor of breast cancer progression
Romaniuk, A. M., & Lyndіn, M. (2015) · Diagnostic Pathology · doi:10.1186/s13000-015-0316-y · Cited by 24 · cited 1×
“Thus, cancer cells are usually addicted to HSP90s to relieve the intracellular stress caused by their malignant lifestyle, which consequently facilitates cancer progression and treatment resistance [35, 36].”
BackgroundA Screening Assay to Identify Agents That Enhance T-Cell Recognition of Human Melanomas
Haggerty, T. J., Dunn, I. S., Rose, L. B., Newton, E. E., & Kurnick, J. T. (2011) · Assay and Drug Development Technologies · doi:10.1089/adt.2011.0379 · Cited by 12 · cited 1×
“On the one hand, HSP90s inhibition could increase the expression of tumor-specific antigens and MHC I-complexed antigens, which synergistically potentiate immunogenicity, thus enhancing tumor surveillance [55, 56].”
BackgroundJarząb, M., Kowal, M., Bal, W., Oczko‐Wojciechowska, M., Rembak-Szynkiewicz, J., Kowalska, M., Stobiecka, E., Chmielik, E., Tyszkiewicz, T., Kaszuba, M., et al. (2017) · Folia Histochemica et Cytobiologica · doi:10.5603/fhc.a2016.0026 · Cited by 8 · cited 1×
“found that low expression of HSP90AA1 and HSP90AB1 might indicate higher sensitivity to chemotherapy and higher probability of pathological complete response in BRAC patients [18].”
Background
Cited by
Recent advances in heat shock proteins in cancer diagnosis, prognosis, metabolism and treatment
Yang, S., Xiao, H., & Cao, L. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112074 · Cited by 121
Chakraborty, A., Mohapatra, S. S., Barik, S., Roy, I., Gupta, B., & Biswas, A. (2023) · Bioscience Reports · doi:10.1042/bsr20220324 · Cited by 53
Zhang, H., Yin, X., Zhang, X., Zhou, M., Xu, W., Wei, Z., Song, C., Han, S., & Han, W. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221118202 · Cited by 40
Shen, L., Huang, H., Li, J., Chen, W., Yao, Y., Hu, J., Zhou, J., Huang, F., & Ni, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1199465 · Cited by 38
Intrinsic RIG-I restrains STAT5 activation to modulate antitumor activity of CD8+ T cells
Jiang, X., Lin, J., Shangguan, C., Wang, X., Xiang, B., Chen, J., Guo, H., Zhang, W., Zhang, J., Shi, Y., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci160790 · Cited by 23
Metadata
- Authors
- Lin, T., Qiu, Y., Peng, W., & Peng, L.
- Affiliations
- Guangzhou University of Chinese Medicine (CN)
- Shenzhen Traditional Chinese Medicine Hospital (CN)
- Corresponding author
- Peng, Lisheng
- Venue
- BioMed Research International
- Publisher
- Wiley
- Published
- 2020-01
- Volume
- 2020
- Issue
- 1
- Pages
- 2148253-2148253
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- PMC
- PMC7596464
- OpenAlex
- W3094633644
- Cited by
- 31
- References
- 57
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 7 · 2023: 9 · 2022: 7 · 2021: 3
- FWCI
- 1.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- BioMed Research International (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- HSP90, Hsp90 isoforms, HSP90AA1, HSP90AB1, HSP90B1, TRAP1, breast cancer, prognostic factors, tumor immune infiltration, tumor microenvironment, basal-like breast cancer, luminal A, CD8+ T cells, tumor-associated macrophages, dendritic cells, neutrophils, antigen processing and presentation, MHC binding, overall survival, recurrence-free survival
- MeSH terms
- Tumor-Associated Macrophages, Atlases as Topic, Breast Neoplasms, Adenocarcinoma, Mucinous, Cell Movement, Dendritic Cells, Female, Humans, Membrane Glycoproteins, Neoplasm Invasiveness, Prognosis, Biomarkers, Tumor, CD4-Positive T-Lymphocytes, Gene Expression Regulation, Neoplastic, Carcinoma, Lobular, CD8-Positive T-Lymphocytes, HSP90 Heat-Shock Proteins, Computational Biology, Databases, Genetic, Carcinoma, Ductal, Molecular Sequence Annotation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.